|
|
|
Teva Pharmaceutical
Industries Ltd. ,
with headquarters in Petach Tikva, Isreal, is among the top 20
pharmaceutical companies and among the largest generic pharmaceutical
companies in the world. The company develops, manufactures and markets
generic and innovative human pharmaceuticals and active pharmaceutical
ingredients. Close to 90% of Teva's sales are in North America and
Europe.
Formerly: Teva
Pharmaceutical Industries Limited
|
|
|
|
DETAILS |
|
|
ETFs |
QQQQ |
|
Sector |
Healthcare |
|
Industry |
|
|
URLs |
http://www.tevapharm.com |
| Ticker |
(NASDAQ: TEVA) |
|
SIC |
2834 - Pharmaceutical
Preparations |
| Founded |
|
|
IPO |
|
| |
|
| Linked to |
|
| |
|
|
|
| |
|
HISTORY |
TYPE |
Divestiture / Closures of Businesses |
|
|
|
|
|
|
|
|
|
HISTORY |
TYPE |
Acquisitions / Strategic Investment |
|
Nov 24, 2005 |
|
Received unconditional approval from the European Commission to
proceed with Teva's acquisition of IVAX. |
|
Oct 27, 2005 |
|
Teva
Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and IVAX
Corporation (AMEX: IVX) announced that, at separate shareholder
meetings held earlier today, their shareholders overwhelmingly
approved the respective proposals submitted to them relating to
the acquisition of IVAX by Teva. In excess of 98% of both the
Teva shares and the IVAX shares voting voted in favor of the
transaction. |
|
Oct 11, 2005 |
|
Received a request for additional information (commonly referred
to as a “second request”) from the U.S. Federal Trade Commission
(FTC) in connection with Teva’s pending acquisition of IVAX. The
effect of the second request is to extend the Hart-Scott-Rodino
Antitrust Improvements Act of 1976 (HSR) waiting period until
thirty days after the parties have substantially complied with
the request, unless that period is terminated sooner by the FTC. |
|
|
|
|
|
Jul 25, 2005 |
DA2A |
IVAX
Corporation (AMEX: IVX) - the terms of the agreement, shares of
IVAX common stock will, at the election of the shareholder, be
converted into either $26 in cash or 0.8471 TEVA ADRs, subject
to proration such that no more than one-half of such elections
are for cash and no more than half are for TEVA ADRs. Based upon
the NASDAQ average closing price of TEVA's ADRs in the 5 days up
to and including July 22, 2005, the transaction has a total
indicated purchase price of approximately $ 7.4 billion. As a
result of the transaction, it is expected that IVAX shareholders
will own approximately 15% of TEVA on a fully-diluted basis. |
|
|
|
|
|
Dec 1, 2004 |
TC |
Pfizer's Italian generic
pharmaceutical marketing company, Dorom S.r.l., one of the
largest suppliers of generic pharmaceuticals to the Italian
retail market. Cash acquisition valued at up to 2.3 times sales-
Dorom’s sales for the 12 months ended June 30, 2004, were
approximately 30 million Euro (approximately $37 million at
current exchange rates). |
|
Jan 22, 2004 |
TC |
Sicor Inc. (Nasdaq: SCRI), which was previously announced on
October 31, 2003 and approved by Sicor's shareholders on January
16, 2004.
|
|
Nov 7, 2003 |
|
Teva
Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today
that it and Savient Pharmaceuticals, Inc. had mutually agreed to
terminate their acquisition discussions because they could not
reach agreement on terms. |
|
Oct 31, 2003 |
DA2A |
SICOR Inc. (Nasdaq: SCRI) - the terms of the agreement, each
share of SICOR common stock will be exchanged for $16.50 in cash
and 0.1906 Teva ADRs. Based upon the NASDAQ closing price of
Teva's ADRs on October 30, 2003, the indicated combined per
share consideration for each outstanding share of SICOR Common
Stock amounts to $27.50, or a total indicated purchase price of
approximately $3.4 billion. As a result of the transaction,
SICOR’s shareholders will come to own approximately 7% of Teva
on a fully-diluted basis. |
|
Oct 3, 2003 |
|
Teva
Pharmaceutical Industries Limited (NASDAQ: TEVA) confirmed today
that it is in discussions concerning the possible acquisition
for cash of Savient Pharmaceuticals, Inc. (NASDAQ:SVNT). The
discussions are at a preliminary stage, and any transaction is
subject to completion of satisfactory due diligence, negotiation
and completion of definitive documentation and other customary
conditions. |
|
Jul 1, 2002 |
TC |
French generic operations of Bayer Pharma S.A. - Bayer Classics
S.A. and a production site located in Sens. - purchase price of
€97 million. |
|
May 21 2002 |
|
Honeywell Pharmaceutical Fine Chemicals S.r.l. (HPFC S.r.l.) -
producer of active pharmaceutical ingredients (API), had total
sales in 2001 of approximately $55 million. | Linked to:
Honeywell International Inc. |
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
